# Long-term Aspirin Therapy as a Predictor of Decreased Susceptibility to SARS-CoV-2 Infection in Aspirin-Exacerbated Respiratory Disease

> **NCT05797597** · PHASE3 · UNKNOWN · sponsor: **Lucyna Mastalerz** · enrollment: 76 (estimated)

## Conditions studied

- AERD - Aspirin Exacerbated Respiratory Disease

## Interventions

- **DRUG:** Aspirin 300 Mg Oral Tablet
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05797597
- **Lead sponsor:** Lucyna Mastalerz
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-07
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 76 (ESTIMATED)
- **Last updated:** 2023-04-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05797597

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05797597, "Long-term Aspirin Therapy as a Predictor of Decreased Susceptibility to SARS-CoV-2 Infection in Aspirin-Exacerbated Respiratory Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05797597. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*